Contracts

All Active Completed

source: current reports (ESPI/EBI) · incomplete data — not every contract is disclosed · 1 contract in the database

DISCLOSED VALUE 12M

—

no contracts with a disclosed value

SHARE OF REVENUE 12M

—

no revenue data in the database

LARGEST COUNTERPARTY

—

no data

LONGEST TERM

—

no realization dates

Excelya

undisclosed

Nowa · Przejęcie roli CRO (Contract Research Organization) prowadzącego badanie kliniczne fazy 1 kandydata na lek viadrudomide (projekt CT-01), w miejsce dotychczasowego usługodawcy

Przejęcie roli CRO (Contract Research Organization) prowadzącego badanie kliniczne fazy 1 kandydata na lek viadrudomide (projekt CT-01), w miejsce dotychczasowego usługodawcy

Status

Ongoing

Signing date

—

Term

—

Report H1 2026

SHOWING 1–1 OF 1

Portfolio summary

Contracts

Active

Total value

—

Average value

—

Since

—

Where this data comes from

Contracts come from current reports (ESPI/EBI) — the company discloses only those exceeding its materiality threshold. The list is by definition incomplete.

Status — inferred from the event type and the term's end date, not a dedicated source field.

Share of revenue 12M — only when both the contracts' dominant currency and the company's reporting currency are PLN, with no currency conversion.

Contracts

Excelya

Portfolio summary

Where this data comes from

See also